Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Novel patterns of response under immunotherapy
E Borcoman, Y Kanjanapan, S Champiat, et al.
ESMO Open
|
November 7, 2025
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
E Borcoman, A Hervieu, C Cropet, et al.
Breast (Edinburgh, Scotland)
|
August 12, 2025
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study
T De La Motte Rouge, J-S Frenel, C Cropet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2019
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
A Moreira, J Masliah-Planchon, C Callens, et al.
ESMO Open
|
June 12, 2021
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
A Moreira, A Poulet, J Masliah-Planchon, et al.
ESMO Open
|
December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas
D M Filippini, B Cabarrou, C Dupain, et al.
ESMO Open
|
April 17, 2021
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
E de Guillebon, M Jimenez, L Mazzarella, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
K Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2019
Novel patterns of response under immunotherapy
E Borcoman, Y Kanjanapan, S Champiat, et al.
ESMO Open
|
November 7, 2025
MOVIE phase II trial of tremelimumab plus durvalumab combined with metronomic oral vinorelbine in patients with head and neck cancer
E Borcoman, A Hervieu, C Cropet, et al.
Breast (Edinburgh, Scotland)
|
August 12, 2025
Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study
T De La Motte Rouge, J-S Frenel, C Cropet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2019
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
A Moreira, J Masliah-Planchon, C Callens, et al.
ESMO Open
|
June 12, 2021
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
A Moreira, A Poulet, J Masliah-Planchon, et al.
ESMO Open
|
December 30, 2025
HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas
D M Filippini, B Cabarrou, C Dupain, et al.
ESMO Open
|
April 17, 2021
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
E de Guillebon, M Jimenez, L Mazzarella, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification
K Rahmani Narj Abadi, C Dupain, I Guillou, et al.
Page
of 1